Fig. 4
From: Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy
cmCAR-T cells exhibited potent target cell-killing activities with increased cytokine release. a, b One day after transfection, anti-CD19 CAR-T cells generated from linear mRNAs, scarred cmRNAs, or scarless cmRNAs were cocultured with NALM-6 or Raji cells (a), and anti-GPRC5D CAR-T cells from the same mRNA platforms were cocultured with MM.1S or RPMI-8226 cells (b). c, d Four days after transfection, anti-CD19 CAR-T cells generated from linear mRNAs, scarred cmRNAs, or scarless cmRNAs were cocultured with NALM-6 or Raji cells (c), and anti-GPRC5D CAR-T cells from the same mRNA platforms were cocultured with MM.1S or RPMI-8226 cells (d). All cocultures were conducted at effector-to-target (E:T) ratios of 1:1, 2:1, and 5:1 for 16 h. e–j IFN-γ release (e), TNF-ɑ release (g), and IL-2 release (I) by linear mRNA-, scarred cmRNA- or scarless cmRNA-based anti-CD19 CAR-T cells after 16 h of coculture with NALM-6 or Raji cells. IFN-γ release (f), TNF-α release (h), and IL-2 release (j) by linear mRNA-based, scarred cmRNA-based or scarless cmRNA-based anti-GPRC5D cells after 16 h of coculture with MM.1S or RPMI-8226 cells. Untransfected (UTD) T cells were used as a negative control. The data are presented as the means ± SDs (n = 3 independent experiments; two-way ANOVA; *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant)
